<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>JUBLINGREA</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">JUBLINGREA</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="jubilant-ingrevia-limited" class="section level1">
<h1>Jubilant Ingrevia Limited</h1>
<p><a href="/reports01/index/industry/rp-SpecialtyChemicals.html">Specialty Chemicals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JUBLINGREA.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JUBLINGREA.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JUBLINGREA.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JUBLINGREA.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JUBLINGREA.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JUBLINGREA.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JUBLINGREA.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JUBLINGREA.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JUBLINGREA.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<div id="jubilant-ingrevia-limited-jublingrea-comprehensive-business-financial-analysis" class="section level9">
<p class="heading"><strong>Jubilant Ingrevia Limited (JUBLINGREA) – Comprehensive Business &amp; Financial Analysis</strong></p>
<p><strong>As of October–November 2025</strong></p>
<hr />
</div>
<div id="executive-summary" class="section level6">
<h6><strong>Executive Summary</strong></h6>
<p>Jubilant Ingrevia Limited is a diversified specialty chemicals player with leadership positions across key segments including <strong>Pyridine &amp; Derivatives, Vitamin B3 (Niacinamide), Acetic Anhydride, and Choline (Vitamin B4)</strong>. The company operates globally, serving pharmaceutical, nutrition, agrochemical, industrial, and consumer markets through its <strong>Custom Development &amp; Manufacturing (CDMO)</strong> platform and nutrition solutions.</p>
<p>Recent quarterly results (Q2 FY26, ended Sept 30, 2025) reflect <strong>robust volume growth, margin resilience, and expanding ESG recognition</strong>, even amid pricing pressures across several chemical segments.</p>
<p>Despite short-term headwinds in pricing, Jubilant is positioned for <strong>multi-year sustainable growth</strong> driven by: - Expansion in high-margin <strong>CDMO business</strong>, - Rising traction from <strong>EU anti-dumping duties on Chinese Choline</strong>, - New capacity coming online (Bharuch CDMO project, Gajraula MPP), - Strategic R&amp;D push into <strong>semi-conductor and cosmetics chemicals</strong>.</p>
<p>The company’s debt has increased moderately, but capital allocation remains focused on long-term value creation.</p>
<hr />
</div>
<div id="tailwinds-growth-drivers" class="section level6">
<h6><strong>1. Tailwinds (Growth Drivers)</strong></h6>
<div id="specialty-chemicals-strong-volume-and-margin-performance" class="section level9">
<p class="heading">✅ <strong>1. Specialty Chemicals: Strong Volume and Margin Performance</strong></p>
<ul>
<li>Revenue: ₹485 Cr (up <strong>12% YoY</strong>, 1% QoQ).</li>
<li>EBITDA: ₹125 Cr (up <strong>44% YoY</strong>) with <strong>25.8% margin</strong>, among the highest in recent quarters.</li>
<li>Key Growth Areas:
<ul>
<li><strong>CDMO &amp; Fine Chemicals</strong>: 10+ molecules added over the past year, with <strong>INR 1,200 Cr+ peak revenue potential</strong>; 10+ more in advanced talks.</li>
<li>Successful shipment under a new <strong>Agro-CDMO innovator contract</strong> – marks commercial validation and future scalability.</li>
<li><strong>Pyridine derivatives</strong>: High double-digit growth (QoQ &amp; YoY).</li>
<li><strong>Diketene derivatives</strong>: Sustained growth momentum.</li>
</ul></li>
<li>CDMO portfolio is expanding into <strong>pharma, agrochemicals, semi-conductors, and cosmetics/nutrition</strong>, reducing client concentration risk.</li>
</ul>
</div>
<div id="nutrition-health-solutions-volume-recovery-eu-market-opportunity" class="section level9">
<p class="heading">✅ <strong>2. Nutrition &amp; Health Solutions: Volume Recovery &amp; EU Market Opportunity</strong></p>
<ul>
<li>Volume Growth: Record sales of <strong>B3 (Niacinamide)</strong> and <strong>B4 (Choline)</strong> despite traditional Q2 seasonality (festivals).</li>
<li>Revenue: ₹181 Cr (~flat YoY), impacted by <strong>temporary pricing weakness</strong> in feed-grade Niacinamide.</li>
<li>Key Tailwinds:
<ul>
<li><strong>EU anti-dumping duties on Chinese Choline</strong> create a significant opening. Jubilant has EU approvals in 3 countries; first shipment already executed.</li>
<li>Increased European inquiries and orders – early signs of demand shift.</li>
<li>New <strong>cGMP facility ramping up</strong>, driving growth in premium <strong>cosmetic-grade B3</strong>, where prices are stable and margins are higher.</li>
</ul></li>
<li>Margins expected to recover as <strong>higher-value products</strong> gain mix share.</li>
</ul>
</div>
<div id="chemical-intermediates-record-volumes-market-share-gains" class="section level9">
<p class="heading">✅ <strong>3. Chemical Intermediates: Record Volumes &amp; Market Share Gains</strong></p>
<ul>
<li>Revenue: ₹455 Cr (highest in 6 quarters), up <strong>6% YoY, 20% QoQ</strong>.</li>
<li>Volumes of <strong>Acetic Anhydride and Ethyl Acetate</strong> at multi-quarter highs.</li>
<li>Cost leadership via:
<ul>
<li><strong>Lean 2.0 initiatives</strong> driving ~INR 100 Cr/year savings.</li>
<li>Lower input costs and improved operating efficiency.</li>
</ul></li>
<li>Despite lower realizations due to market oversupply, EBITDA was stable <strong>QoQ at ₹20 Cr</strong> (margin: 4.3%).</li>
</ul>
</div>
<div id="operational-excellence-esg-leadership" class="section level9">
<p class="heading">✅ <strong>4. Operational Excellence &amp; ESG Leadership</strong></p>
<ul>
<li><strong>Green Power Impact</strong>: Power &amp; fuel costs <strong>down 16% YoY</strong>, while volume grew.
<ul>
<li>Renewable energy now at <strong>28%</strong> of power mix (new O₂ power plant in Bharuch commissioned).</li>
</ul></li>
<li><strong>ESG Recognition</strong>: Won <strong>ICC Sustainability Award in Water Stewardship</strong>.</li>
<li><strong>Global Lighthouse Network (WEF)</strong> member since 2024 – recognition of Industry 4.0 tech deployment.</li>
</ul>
</div>
<div id="innovation-rd-pipeline-momentum" class="section level9">
<p class="heading">✅ <strong>5. Innovation &amp; R&amp;D Pipeline Momentum</strong></p>
<ul>
<li><strong>~50 products in R&amp;D pipeline</strong>.</li>
<li><strong>18 new product launches expected in FY26</strong>.</li>
<li>R&amp;D centers in G. Noida and Gajraula scaling up.</li>
<li>Entry into <strong>high-growth semiconductor chemicals</strong>, signaling diversification into tech-intensive specialty markets.</li>
</ul>
</div>
<div id="global-customer-diversification-kam-progress" class="section level9">
<p class="heading">✅ <strong>6. Global Customer Diversification &amp; KAM Progress</strong></p>
<ul>
<li>Customer base across <strong>US, EU, Japan, Middle East, SE Asia</strong>.</li>
<li><strong>KAM funnel expanded to 100+ opportunities</strong> (from 70 in Q1).</li>
<li>Peak revenue potential: <strong>₹3,500 Cr+</strong>; 20+ confirmed/pipeline molecules.</li>
</ul>
<hr />
</div>
</div>
<div id="headwinds-challenges" class="section level6">
<h6><strong>2. Headwinds &amp; Challenges</strong></h6>
<div id="pricing-pressures-across-segments" class="section level9">
<p class="heading">❌ <strong>1. Pricing Pressures Across Segments</strong></p>
<ul>
<li><strong>Pyridine &amp; Picoline prices</strong>: Temporarily soft in Q2 due to volatility; expected to recover.</li>
<li><strong>Feed-grade vitamins (B3)</strong>: Pricing volatility globally due to competitive volume push.</li>
<li><strong>Ethyl Acetate &amp; Acetic Anhydride</strong>: Prices subdued due to oversupply and pass-through of lower raw material costs (acetic acid).</li>
<li>These factors led to <strong>lower YoY EBITDA in Chemical Intermediates (-51%)</strong> despite volume growth.</li>
</ul>
</div>
<div id="ebitda-decline-qoq-in-q2-fy26" class="section level9">
<p class="heading">❌ <strong>2. EBITDA Decline QoQ in Q2 FY26</strong></p>
<ul>
<li>Total EBITDA: ₹146 Cr (down <strong>5% QoQ</strong>) vs ₹153 Cr in Q1 FY26.</li>
<li>Driven by:
<ul>
<li>Price softening in pyridine and derivatives.</li>
<li>Temporary <strong>shutdown at pyridine plant</strong> in Q2.</li>
<li>Mix impact from nutrition and intermediates.</li>
</ul></li>
<li>However, <strong>EBITDA still grew 8% YoY</strong>, showing underlying strength.</li>
</ul>
</div>
<div id="competitive-pressure-in-nutrition-segment" class="section level9">
<p class="heading">❌ <strong>3. Competitive Pressure in Nutrition Segment</strong></p>
<ul>
<li>Nutrition revenue declined <strong>2% YoY</strong> in H1 (~₹359 Cr) due to aggressive competition from China and others.</li>
<li>Margins compressed (11.6% in Q2 vs 13.9% in Q1), though recovery expected on <strong>product mix improvement</strong> and <strong>EU tariffs on China</strong>.</li>
</ul>
</div>
<div id="rising-net-debt" class="section level9">
<p class="heading">❌ <strong>4. Rising Net Debt</strong></p>
<ul>
<li><strong>Net debt: ₹748 Cr</strong> as of Sept 2025 (vs ₹658 Cr a year ago) → <strong>+15% YoY</strong>.</li>
<li>Driven by capex for upcoming projects:
<ul>
<li>Bharuch CDMO plant (₹109 Cr spent in H1 FY26).</li>
<li>$300 Mn Agro-innovator project (on track for Q4 FY26 commissioning).</li>
</ul></li>
<li>While debt is increasing, <strong>Ebitda growth is strong (18% H1 YoY)</strong>, improving coverage.</li>
</ul>
<hr />
</div>
</div>
<div id="growth-prospects-20252027" class="section level6">
<h6><strong>3. Growth Prospects (2025–2027)</strong></h6>
<table>
<colgroup>
<col width="27%" />
<col width="72%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Area</strong></th>
<th><strong>Growth Catalyst</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>CDMO Business</strong></td>
<td>- Major order expected to start <strong>early 2026</strong>.<br> - 10+ new molecules with <strong>₹1,200 Cr peak revenue</strong>.<br> - New <strong>MPP plant in Gajraula</strong> (2026 completion).</td>
</tr>
<tr class="even">
<td><strong>Nutrition</strong></td>
<td>- <strong>EU shift away from Chinese Choline</strong>: significant volume upside.<br> - Higher-margin <strong>cosmetic-grade B3</strong> ramping up.<br> - Premixes and specialty offerings gaining traction.</td>
</tr>
<tr class="odd">
<td><strong>Specialty Chemicals</strong></td>
<td>- Pyridine and diketene derivatives growing strongly.<br> - Entry into <strong>semi-conductor chemicals</strong> – large growth potential.</td>
</tr>
<tr class="even">
<td><strong>Operations</strong></td>
<td>- Renewable energy reduces power costs and carbon footprint.<br> - Lean 2.0 savings → ~₹100 Cr/year benefit continuing.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="key-risks" class="section level6">
<h6><strong>4. Key Risks</strong></h6>
<table>
<colgroup>
<col width="62%" />
<col width="37%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Risk Category</strong></th>
<th><strong>Details</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Macroeconomic Risks</strong></td>
<td>- Sluggish demand in <strong>Europe</strong> (plant closures, weak energy outlook).<br> - Global inflation, FX volatility (USD ~₹88.79 in Q2).</td>
</tr>
<tr class="even">
<td><strong>Input Cost Volatility</strong></td>
<td>- Though raw material costs are low now, any reversal (e.g. acetic acid) could compress margins.</td>
</tr>
<tr class="odd">
<td><strong>Execution Risk on Capex</strong></td>
<td>- Delay in Bharuch CDMO or Gajraula MPP could impact growth timeline.</td>
</tr>
<tr class="even">
<td><strong>CDMO Order Ramp-Up Risk</strong></td>
<td>- Initial revenues from large CDMO projects may be slower than expected.</td>
</tr>
<tr class="odd">
<td><strong>Regulatory Risks</strong></td>
<td>- Anti-dumping benefits in EU may not be sustained long-term.<br> - Need continuous compliance across geographies (USFDA, EU, etc.).</td>
</tr>
<tr class="even">
<td><strong>Competition</strong></td>
<td>- Chinese exporters may undercut pricing in vitamins and intermediates despite duties.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="financial-snapshot-q2-h1-fy26" class="section level6">
<h6><strong>5. Financial Snapshot (Q2 &amp; H1 FY26)</strong></h6>
<table>
<colgroup>
<col width="27%" />
<col width="10%" />
<col width="10%" />
<col width="10%" />
<col width="9%" />
<col width="10%" />
<col width="10%" />
<col width="9%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Metric (INR Cr unless stated)</strong></th>
<th><strong>Q2 FY25</strong></th>
<th><strong>Q1 FY26</strong></th>
<th><strong>Q2 FY26</strong></th>
<th><strong>YoY Δ</strong></th>
<th><strong>H1 FY25</strong></th>
<th><strong>H1 FY26</strong></th>
<th><strong>YoY Δ</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue</strong></td>
<td>1,045</td>
<td>1,038</td>
<td><strong>1,121</strong></td>
<td><strong>+7%</strong></td>
<td>2,070</td>
<td><strong>2,159</strong></td>
<td><strong>+4%</strong></td>
</tr>
<tr class="even">
<td><strong>EBITDA</strong></td>
<td>135</td>
<td>153</td>
<td><strong>146</strong></td>
<td><strong>+8%</strong></td>
<td>254</td>
<td><strong>300</strong></td>
<td><strong>+18%</strong></td>
</tr>
<tr class="odd">
<td><strong>EBITDA Margin</strong></td>
<td>12.9%</td>
<td>14.8%</td>
<td><strong>13.1%</strong></td>
<td>—</td>
<td>12.3%</td>
<td><strong>13.9%</strong></td>
<td>—</td>
</tr>
<tr class="even">
<td><strong>Profit After Tax (PAT)</strong></td>
<td>59</td>
<td>75</td>
<td><strong>70</strong></td>
<td><strong>+18%</strong></td>
<td>108</td>
<td><strong>145</strong></td>
<td><strong>+34%</strong></td>
</tr>
<tr class="odd">
<td><strong>EPS (Basic)</strong></td>
<td>3.7</td>
<td>4.7</td>
<td><strong>4.4</strong></td>
<td><strong>+18%</strong></td>
<td>6.8</td>
<td><strong>9.2</strong></td>
<td><strong>+34%</strong></td>
</tr>
</tbody>
</table>
<ul>
<li><strong>Capex</strong>: ₹109 Cr in H1 FY26 (₹59 Cr in Q2), focused on CDMO and agri projects.</li>
<li><strong>Net Debt</strong>: ₹748 Cr (up from ₹650 Cr YoY), but manageable with rising EBITDA.</li>
</ul>
<hr />
</div>
<div id="leadership-governance" class="section level6">
<h6><strong>6. Leadership &amp; Governance</strong></h6>
<ul>
<li><strong>Founders actively involved</strong>: Shyam S. Bhartia (Chairman), Hari S. Bhartia (Co-Chairman &amp; Whole Time Director).</li>
<li><strong>Experienced leadership team</strong>: Deepak Jain (CEO &amp; MD, 20+ years), supported by seasoned business heads (20+ years avg).</li>
<li><strong>Proactive investor communication</strong>: Regular disclosures, earnings calls, granular updates.</li>
<li><strong>Stock incentive alignment</strong>: Recent grant of <strong>123,704 stock options/RSUs</strong> – shows focus on employee retention and performance alignment.</li>
</ul>
<hr />
</div>
<div id="conclusion-investment-thesis-for-jublingrea" class="section level6">
<h6><strong>Conclusion: Investment Thesis for JUBLINGREA</strong></h6>
<div id="bull-case" class="section level9">
<p class="heading">✅ <strong>Bull Case</strong></p>
<ul>
<li><strong>Sustainable double-digit growth</strong> in specialty chemicals and nutrition.</li>
<li><strong>Margin expansion likely</strong> from CDMO, cosmetic/nutrition grades, operational efficiency.</li>
<li><strong>Strong tailwinds in EU Choline</strong>, CDMO, and semi-conductor diversification.</li>
<li>ESG leadership enhances global competitiveness.</li>
</ul>
</div>
<div id="neutral-caution-points" class="section level9">
<p class="heading">⚠️ <strong>Neutral / Caution Points</strong></p>
<ul>
<li>Valuations may need to digest capex cycle and debt build-up.</li>
<li>Short-term earnings volatility due to pricing swings.</li>
<li>Execution risk on major new projects.</li>
</ul>
</div>
<div id="bear-case" class="section level9">
<p class="heading">❌ <strong>Bear Case</strong></p>
<ul>
<li>Prolonged downturn in European chemical demand.</li>
<li>Pricing wars resuming from Chinese players in vitamins or intermediates.</li>
<li>Delays in major CDMO or export contracts.</li>
</ul>
<hr />
</div>
<div id="final-verdict-buy-long-term-hold" class="section level9">
<p class="heading"><strong>Final Verdict: BUY (Long-Term Hold)</strong></p>
<p><strong>Target Horizon: 2–3 years</strong></p>
<p>Jubilant Ingrevia is evolving from a <strong>commodity chemical player</strong> to a <strong>high-value specialty and CDMO leader</strong>, with multiple growth levers firing. It is <strong>well-positioned for margin resilience and volume growth</strong>, supported by favorable regulatory shifts and innovation.</p>
<p>While near-term pricing headwinds caused a <strong>QoQ EBITDA dip</strong>, the company is <strong>delivering strong PAT momentum (18% YoY, 34% H1)</strong> and investing wisely for the future.</p>
<blockquote>
<p><strong>Key Catalysts Ahead</strong>:<br />
- <strong>Early 2026</strong>: Start of major CDMO order.<br />
- <strong>H2 FY26</strong>: Recovery in Acetyls profitability.<br />
- <strong>2026–27</strong>: New MPP plant and semiconductor R&amp;D.</p>
</blockquote>
<hr />
</div>
<div id="for-further-monitoring" class="section level9">
<p class="heading"><strong>For Further Monitoring</strong>:</p>
<table>
<colgroup>
<col width="31%" />
<col width="68%" />
</colgroup>
<thead>
<tr class="header">
<th>Signal</th>
<th>Key Indicator</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>✅ Positive</td>
<td>- Progress on EU Choline sales ramp-up.<br> - CDMO revenue traction.<br> - Reduction in net debt/EBITDA ratio.</td>
</tr>
<tr class="even">
<td>❌ Warning</td>
<td>- Further EBITDA margin decline.<br> - Capex overruns.<br> - Renewed price war in B3 or Acetic Anhydride.</td>
</tr>
</tbody>
</table>
<hr />
<p><strong>Sources</strong>: Q2 FY26 Results Press Release, Investor Presentation (October 27, 2025), Stock Option Grant &amp; CP Redemption Notices, Jubilant Ingrevia website.<br />
<strong>Published</strong>: November 2025<br />
<strong>For Public Disclosure</strong> – <em>Forward-Looking Statements Disclaimer Included per SEBI Regulations.</em></p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
